Mustang Bio to Present at the CAR-TCR Summit 2017

NEW YORK, Sept. 05, 2017 -- Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, today announced that the Company will present and also participate in a panel session at the CAR-TCR Summit 2017, to be held September 5-8 at the Seaport Hotel & World Trade Center in Boston. 

Details on the oral presentation are as follows:

Title: CAR T Cell Therapy for Brain Tumors: Logistical Challenges and Opportunities
Presenter: Sadik Kassim, Ph.D., Vice President, Process and Analytical Development, Mustang Bio, Inc.
Track: CAR-TCR Commercialization Stream
Date and Time: Wednesday, September 6, 2017, 11:50 a.m. – 12:20 p.m. EDT
Location: Waterfront 2/3 Room

Details on the panel session are as follows:

Title: What are the next generation innovations to improve solid tumor efficacy?
Panelist: Sadik Kassim, Ph.D., Vice President, Process and Analytical Development, Mustang Bio, Inc.
Track: CAR-TCR Discovery Stream
Date and Time: Wednesday, September 6, 2017, 5:50 p.m. – 6:50 p.m. EDT
Location: Cityview Room

For additional information on the CAR-TCR Summit 2017, please visit: http://car-tcr-summit.com/.

About Mustang Bio
Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient’s own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and outlicensing or bringing the technologies to market. Mustang is currently developing proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) technology, which was licensed from Drs. Stephen Forman and Christine Brown’s laboratory at the City of Hope National Medical Center (“COH”). Mustang and COH have established a research agreement to develop CARs across multiple cancers. Mustang’s lead programs are in Phase 1 trials at COH: MB-101 for the treatment of brain cancer, and MB-102 as a therapeutic agent in acute myeloid leukemia. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission. For more information, visit www.mustangbio.com.

About Fortress Biotech
Fortress Biotech, Inc. (“Fortress”) is a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress develops and commercializes products both within Fortress and through certain of its subsidiary companies, also known as Fortress Companies. In addition to its internal development programs, Fortress leverages its biopharmaceutical business expertise and drug development capabilities and provides funding and management services to help the Fortress Companies achieve their goals. Fortress and the Fortress Companies may seek licensings, acquisitions, partnerships, joint ventures and/or public and private financings to accelerate and provide additional funding to support their research and development programs. For more information, visit www.fortressbiotech.com.

Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs, and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: the risk that Mustang will not be able to advance its research programs; risks related to the timing of starting and completing of clinical trials; risks inherent in research and development activities; risks related to its growth strategy; its ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; its dependence on third-party suppliers; its ability to attract, integrate, and retain key personnel; the early stage of products under development; its need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in Mustang’s public filings and reports. Mustang expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

Contacts: 
Jaclyn Jaffe
Mustang Bio, Inc.
(781) 652‐4500 
[email protected]

Fortress Biotech Media Relations
Laura Bagby
6 Degrees
(312) 448-8098
[email protected]